This is a securities class action lawsuit against Schering-Plough.
Schering-Plough engages in the discovery, development, manufacture, and marketing of medical therapies and treatments worldwide.
The securities class action lawsuit alleges that Schering-Plough failed to disclose and misrepresented material adverse facts thereby artificially inflating the value of Schering Plough shares during the Class Period. Specifically, the complaint alleges that, during the Class Period, Schering-Plough misled investors regarding the increased efficacy of Vytorin, a combination of Zetia and Zocor, over the cheaper generic form of Zocor (simvastatin), alone, and delayed disclosing results of the ENHANCE study demonstrating that Vytorin was not more efficacious than Zocor. Schering Plough knew that the ENHANCE study did not meet its endpoints, yet hid this fact from the investor community for over a year and made repeated positive statements about the study during that time frame.
Name (Stock Symbol)
Schering-Plough Corporation (SGP)
Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.